Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Tax Provisions (2016 - 2026)

United Therapeutics' Tax Provisions history spans 17 years, with the latest figure at $79.7 million for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 16.28% to $79.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $379.2 million, a 10.26% increase, with the full-year FY2025 number at $379.2 million, up 10.26% from a year prior.
  • Tax Provisions hit $79.7 million in Q4 2025 for United Therapeutics, down from $99.3 million in the prior quarter.
  • Over the last five years, Tax Provisions for UTHR hit a ceiling of $101.3 million in Q1 2025 and a floor of $4.2 million in Q1 2021.
  • Historically, Tax Provisions has averaged $67.7 million across 5 years, with a median of $76.6 million in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 87.61% in 2021 and later skyrocketed 1538.1% in 2022.
  • Tracing UTHR's Tax Provisions over 5 years: stood at $28.3 million in 2021, then surged by 65.02% to $46.7 million in 2022, then surged by 67.67% to $78.3 million in 2023, then grew by 21.58% to $95.2 million in 2024, then fell by 16.28% to $79.7 million in 2025.
  • Business Quant data shows Tax Provisions for UTHR at $79.7 million in Q4 2025, $99.3 million in Q3 2025, and $98.9 million in Q2 2025.